Skip to main content

Table 5 HPV-capsid antibodies in subgroups of HIV-positive men stratified by CD4 counts or high active antiretroviral therapy (HAART)

From: High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study

HPV antibodies   cumulative low risk (6, 11) cumulative high risk (16, 18, 31)
CD4+ cells <200 /μl (n = 42) 8 (19,0%) 17 (40,4%)
CD4+ cells 200–400/μl (n = 61) 16 (26,2%) 24 (39,3%)
CD4+ cells <200 /μl (n = 65) 16 (24,6%) 25 (38,4%)
with HAART (n = 96) 26 (27,1%) 42 (43,7%)*
without HAART (n = 72) 14 (19,4%) 24 (33,3%)*
  1. *p = 0.2, Odds ratio (95% CI), 1.6 (0.8–2.9)